Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

16 Dec 2008 07:00

RNS Number : 1787K
ViaLogy PLC
16 December 2008
 



ViaLogy PLC ("ViaLogy" or "the Company")

ViaLogy reports 'significant technical progress' in Interim Report

December 16th 2008. ViaLogy PLC today issued its Interim Report for the six-month period to September 30, 2008. The Company showed a loss for the period of £2,597,102, which included £1,176,605 for amortisation and depreciation. The amortisation charge relates to the value of ViaLogy's Intellectual Property and associated Research and Development, which is amortised over a total of six years. The cash outflow from operations during the six months was £1,348,898.

In a trading update accompanying the report ViaLogy's Chief Executive, Robert W. Dean, said that considerable progress is being made in the two sectors where it is focussing its principal commercial efforts, Safety and Security, and Oil and Gas. Working closely with San Antonio-based partner Atascosa Exploration LLP, ViaLogy has determined the location of an additional hydrocarbon gas reservoir. Using QuantumRD, ViaLogy's proprietary technology for geoseismic analysis that assesses the location, capacity and payout of hydrocarbon reservoirs, Atascosa plans to complete drilling in January 2009. ViaLogy is also fixing the location of another oil reservoir for Atascosa, and determining the optimal drill location. Drilling on this second project should also be completed in the January/February 2009 timeframe.

"Success with these projects will give ViaLogy a 5% working interest in their output, and should mark a major milestone in proof-of-concept acceptance of the QuantumRD technology by the oil and gas exploration industry," said Mr. Dean. "ViaLogy intends to market its QuantumRD product aggressively, and to enter immediately into additional drilling projects with Atascosa."

Mr. Dean also confirmed significant progress in productizing ViaLogy's core Intellectual Property, Quantum Resonance Interferometry (QRI™), with its application to precisely geolocate buried oil and gas pipeline. This application of QRI™ is branded as QSUB™. QRI™ itself is a tool for the extraction of hard-to-find information from sensor data that frustrate other software processing techniques; it has wide applicability in that it can be applied to data from virtually any type of sensor. Precisely locating buried pipeline more cost effectively than current techniques is a business service for which ViaLogy believes there is a substantial market, and for which ViaLogy believes QSUB™ has a direct and cost-cutting application. ViaLogy's work over the last six months has been to demonstrate a new approach that is dependable, robust, and meets pipeline industry criteria. 

"We have not encountered any setback with the application of the QRI™ technology," said Mr. Dean. "Working within ViaLogy's resource constraints, and using multiple synthetic aperture radar data sets to confront the technology with a demanding variety of soil conditions, ViaLogy is showing that QSUB™  can both locate otherwise impossible-to-find buried metal objects, and improve radar's performance by determining when it produces false alarms. This work translates directly into the pipeline application. We hope to be able to report major milestones in the first quarter of 2009 about carrying the pipeline business forward."

In the Physical Security Information Management market, ViaLogy's flagship security software product SPM™ (Sensor Policy Manager™) has made major steps forward in the face of economic and business challenges in the security software business stemming from difficulties in the wider economy. "Our Canadian partner Axia Supernet has decided to expand a joint SPM™ air quality monitoring operational pilot as a step toward winning customer acceptance of a province-wide deployment. SPM™ is operating in Los Angeles County as the core piece of a chemical toxin early warning system sponsored by the US Department of Health & Safety and the Company expects this system to be expanded in LA County and further deployed to other major US cities. In cooperation with a major US defense contractor, ViaLogy has successfully integrated multiple perimeter surveillance radars into an Air Force Asian base security system and ViaLogy expects further orders for other bases; SPM™ is also being evaluated for supporting US Army base security systems. In addition, one of  ViaLogy's partners, Cisco Systems Inc, has put in place a targeted marketing effort for its COPSS integrated security solution; SPM™ is an integral part of COPSS and Cisco Systems Inc and ViaLogy are jointly approaching major potential customers. In summary, the Company has a growing sales pipeline for its SPM™ and looks toward substantial income in 2009.

Commenting on the Interim Report, ViaLogy's chairman, Terry Bond, said the board was pleased with the continuing progress being made by the company. In August 2008 ViaLogy raised £1.8 million by way of a placing of 45 million new ordinary shares at 4p per share. In addition, subject to shareholder approval which was subsequently given at the AGM, the placees received one warrant for every ordinary share purchased in the placing. Each warrant entitles the holder to purchase an additional ordinary share at 5p at any time up to 29 October 2011.

"Our work throughout 2008 has been carried out in an international financial and commercial environment that is the most difficult I have ever experienced," said Mr. Bond. "In such circumstances it is incumbent upon small companies such as ViaLogy, with a strong technology potential but yet to make its commercial mark, to be prudent in its financial planning. We have looked carefully at every aspect of our overhead expenditure and made cost savings wherever possible. In addition, directors and staff have agreed to make personal financial sacrifices to ensure the continued well-being of the Company and I thank them on behalf of the board and the shareholders."

For further information please contact:

ViaLogy

Robert W. Dean, President and CEO - US. +1 626-296-6337

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Adviser (Seymour Pierce)

Mark Percy +44 (0) 207-107-8000

Brokers

St. Helens Capital +44 (0) 207-628-5582

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGUGCAPUPRGQA
Date   Source Headline
30th Nov 201511:20 amRNSNotice of Results
12th Nov 20157:00 amRNSPositive independent study results for IONA test
28th Oct 20157:00 amRNSAppointment to the Board
15th Oct 20153:56 pmRNSWorld first: in-house antenatal reflex screening
14th Oct 20157:00 amRNSClinical laboratory with expanded capacity opened
14th Oct 20157:00 amRNSHolding(s) in Company
13th Oct 20154:08 pmRNSResult of AGM
13th Oct 20152:20 pmRNSHolding(s) in Company
13th Oct 20157:01 amRNSAGM Statement
13th Oct 20157:00 amRNSPremaitha collaborates with Wolfson screening lab
12th Oct 20157:00 amRNSIndependent study of the IONA® test published
2nd Oct 20157:00 amRNSPremaitha appoints Greek distributor
1st Oct 20154:14 pmRNSPatent Infringement Proceedings Update
22nd Sep 20157:00 amRNSFinal Results
22nd Sep 20157:00 amRNSPremaitha signs contract for IONA test in Chile
15th Jul 20157:00 amRNSGrant of Options
13th Jul 20152:04 pmRNSHolding(s) in Company
6th Jul 20157:00 amRNSCQC accreditation for new NIPT lab
2nd Jul 20152:59 pmRNSCompletion of placing to raise £8 million
2nd Jul 20157:00 amRNSProposed placing to raise approximately £8 million
24th Jun 20157:00 amRNSNew IONA test clinical data showcased
22nd Jun 20157:00 amRNSNew contract for IONA® test
19th Jun 20157:00 amRNSTrading Update
4th Jun 20157:00 amRNSAppointment of Chief Financial Officer
5th May 20157:01 amRNSPremaitha Files Robust Defence with UK High Court
29th Apr 20151:53 pmRNSReissue of Options
31st Mar 20157:00 amRNSNew Contract for IONA test in Poland
23rd Mar 20159:53 amRNSLondon NHS trust teams up with Premaitha Health
16th Mar 20159:40 amRNSNotice of Patent Infringement Proceedings
16th Mar 20157:00 amRNSPremaitha Health signs first NIPT agreement
5th Feb 20157:00 amRNSCE Mark and Launch of the IONA test
30th Jan 20157:00 amRNSCommercial Launch Preparation Update
10th Dec 20147:00 amRNSResults for 7 months to 30 September 2014
25th Nov 20147:00 amRNSNotice of Half Year Results and IONA Test Showcase
4th Nov 201412:07 pmRNSResult of AGM
4th Nov 20147:00 amRNSAGM Statement
2nd Oct 20147:00 amRNSGrant of Options
30th Sep 20147:00 amRNSPublication of Annual Report and Notice of AGM
7th Jul 20144:47 pmRNSHolding(s) in Company
4th Jul 20144:28 pmRNSHolding(s) in Company
4th Jul 20147:00 amRNSFirst Day of Dealings on AIM
3rd Jul 20143:42 pmRNSChange of Name
3rd Jul 201411:36 amRNSResult of EGM
1st Jul 201410:47 amRNSOpen Offer Oversubcribed
13th Jun 20147:30 amRNSRestoration - ViaLogy Plc
13th Jun 20147:30 amRNSSchedule 1 - ViaLogy Plc
13th Jun 20147:00 amRNSPublication of Admission Document & Lifting of...
13th Jun 20147:00 amRNSDirectorate Change
13th Jun 20147:00 amRNSFinal Results
15th Apr 201412:30 pmRNSSuspension - Vialogy plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.